Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
| العنوان: | Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers |
|---|---|
| المؤلفون: | Eitan Friedman, Peter Ainsworth, Ava Kwong, Jacek Gronwald, Sofia D. Merajver, John Lunn, Andrea Eisen, Talia Donenberg, Wendy S. Meschino, Rochelle Demsky, Taya Fallen, Fergus J. Couch, Joanne L. Blum, Albert E. Chudley, Charis Eng, Raluca N. Kurz, Kelly A. Metcalfe, Mary B. Daly, Aletta Poll, Howard M. Saal, Louise Bordeleau, André Robidoux, A Jakubowska, Steven A. Narod, Tomasz Byrski, Claudine Isaacs, Charmaine Kim-Sing, Jane McLennan, Kenneth Offit, Dominique Stoppa-Lyonnet, Nadine Tung, Robert E. Reilly, Daniel Rayson, Edmond G. Lemire, Marie E. Wood, Jan Klijn, Siranoush Manoukian, Barry P. Rosen, Gad Rennert, Gareth Evans, Susan Armel, Ruth Gershoni-Baruch, Pål Møller, Jan Lubinski, Mark E. Robson, Sonia Nanda, Beth Y. Karlan, Barbara Pasini, Henry T. Lynch, Kevin Sweet, Leigha Senter, Christian F. Singer, Ping Sun, Judy Garber, Lovise Maehle, Josephine Wagner Costalas, Ophira Ginsburg, Dawna Gilchrist, Tomasz Huzarski, Wendy McKinnon, Jeffrey N. Weitzel, William D. Foulkes, Susan L. Neuhausen, Noah D. Kauff, Christine Rappaport, Carey A. Cullinane, David M. Euhus, Tuya Pal, Dana Zakalik, Olufunmilayo I. Olopade, Seema Panchal, Cezary Cybulski, Susan T. Vadaparampil |
| المصدر: | Breast Cancer Research and Treatment. 146:421-427 |
| بيانات النشر: | Springer Science and Business Media LLC, 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Adult, Oncology, Heterozygote, Cancer Research, medicine.medical_specialty, Time Factors, Antineoplastic Agents, Hormonal, medicine.medical_treatment, Genes, BRCA2, Genes, BRCA1, Breast Neoplasms, Article, Contralateral breast cancer, Breast cancer, BRCA2 Mutation, Risk Factors, Internal medicine, Odds Ratio, medicine, Humans, skin and connective tissue diseases, Aged, business.industry, Case-control study, Cancer, Oophorectomy, Neoplasms, Second Primary, Odds ratio, Middle Aged, medicine.disease, Tamoxifen, Case-Control Studies, Mutation, Female, business, medicine.drug |
| الوصف: | Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of approximately 80 %. Tamoxifen treatment of the first cancer has been associated with a reduction in the risk of a subsequent contralateral cancer. We studied 1,504 women with a known BRCA1 or BRCA2 mutation, 411 women with bilateral breast cancer (cases) and 1,093 women with unilateral breast cancer (controls) in a matched case-control study. Control women were of similar age and had a similar age of diagnosis of first breast cancer as the cases. For each woman who used tamoxifen, the starting and stopping dates were abstracted and the duration of tamoxifen use was calculated. Three hundred and thirty-one women had used tamoxifen (22 %); of these 84 (25 %) had completed four or more years of tamoxifen, the remainder stopped prematurely or were current users. For women with up to 1 year of tamoxifen use, the odds ratio for contralateral breast cancer was 0.37 (95 % CI 0.20-0.69; p = 0.001) compared to women with no tamoxifen use. Among women with 1-4 years of tamoxifen use the odds ratio was 0.53 (95 % CI 0.32-0.87; p = 0.01). Among women with four or more years of tamoxifen use the odds ratio was 0.83 (95 % CI 0.44-1.55; p = 0.55). Short-term use of tamoxifen for chemoprevention in BRCA1 and BRCA2 mutation carriers may be as effective as a conventional 5-year course of treatment. |
| تدمد: | 1573-7217 0167-6806 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce7b5df22a2dfdec890e6aaef924df2a https://doi.org/10.1007/s10549-014-3026-3 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....ce7b5df22a2dfdec890e6aaef924df2a |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 15737217 01676806 |
|---|